By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Using a glucose metre to measure the amount of glucose in the blood is known as blood glucose monitoring (glycemia). A blood glucose test is normally conducted by piercing the skin (often on the finger) to extract blood, then putting the blood to a disposable, chemically active “test-strip.” This procedure is particularly significant in the management of diabetes.
While different manufacturers employ various technologies, the majority of devices measure an electrical characteristic and utilise this information to calculate the blood glucose level. Typically, the test is known as a capillary blood glucose test.
The interstitial fluid, which is connected to the capillary system and has the same levels of glucose as blood vessels but with a time lag of a few minutes, can also be used to test glucose concentrations. However, implants cannot directly employ the enzymatic glucose detection method used in single-use test strips. One major issue is the fluctuating oxygen levels, as glucose oxidase converts glucose to gluconolactone and H2O2 during this process.
The diffusion of oxygen to the reaction zone is continuously reduced because the implantation of a sensor into the body is followed by the formation of encapsulating tissue. Due to the sensor reading drifting as a result of the declining oxygen availability, periodic finger-stick and test strips calibration is needed.
The Global Real time glucose monitoring system market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
Abbott launched the FreeStyle Libre continuous glucose monitoring (CGM) device. Adults, kids (over the age of four), and pregnant women with gestational diabetes can all use it (diabetes during pregnancy). The 5.5mm long filament of the FreeStyle Libre sensor, which is inserted just beneath the skin and secured in place with a small adhesive pad, measures glucose in interstitial fluid once every minute.
A complete picture of a person’s glucose levels can be obtained by quickly scanning the sensor with a reader to obtain a real-time glucose reading on demand. With the help of this device, diabetics are freed from the uncomfortable daily calibration or routine fingersticks, allowing them to make real lifestyle and therapy changes.
The new Dexcom ONE Continuous Glucose Monitoring System was introduced by DexCom, a company that specialises in real-time continuous glucose monitoring for persons with diabetes. A wearable sensor and transmitter called Dexcom ONE gives users complete control over their diabetes.
The technology does away with the necessity for uncomfortable finger pricks by continually monitoring glucose levels and wirelessly transmitting real-time readings to a compatible smart device via the Dexcom ONE mobile app.
In order to make treatment options more straightforward in the present, the app displays trend arrows to highlight the pace and direction glucose levels are travelling in. Users can avoid potentially dangerous high or low glucose occurrences with the help of a variety of customizable alarms.
The leader in real-time continuous glucose monitoring (CGM), Dexcom, and Zillion announced their agreement in order to integrate Dexcom CGM with Zillion’s platform for usage with their RestoreHealth programme. Through this agreement, RestoreHealth’s services for employees and patients of healthcare systems will continue to improve.
A professional continuous glucose monitor (CGM) for persons with type 2 diabetes is currently being developed by Medtronic and Qualcomm as part of a global partnership.
A product that is single-use (totally disposable), prescribed at a doctor’s office, worn once or once a week every six months or so, much less expensive, a lot simpler to start up and use, and smaller to wear on the body is something they aim to release soon.
An integrated automated insulin delivery (AID) system will be created by Abbott in collaboration with CamDiab and Ypsomed, according to a press release. It aims to create and market the integrated AID system, initially concentrating on European nations.
In order to connect Abbott’s FreeStyle Libre 3 sensor, which is marketed as the world’s smallest and most accurate continuous glucose monitoring sensor (CGM) with readings every minute, to CamDiab’s CamAPS FX mobile app, which connects with Ypsomed’s mylife YpsoPump, the two companies will develop an integrated AID system.
